Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 May 12;10(12):3873–3885. doi: 10.1002/cam4.3929

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Molecular profile of circulating tumor DNA in plasma samples from patients prior to osimertinib treatment. Fifty‐four patients are shown among whom NGS was successful, from among 57 patients treated with osimertinib, including 3 CR, 27 PR, 19 SD, and 4 PD patients. One patient could not be evaluated for tumor response because of accidental development of cerebral infarction. Single‐nucleotide variants or insertions/deletions deemed to be oncogenic, likely oncogenic, or predicted oncogenic by OncoKB are included. NE, not evaluated; PD, progressive, disease; SD, stable disease; PR, partial response; CR, complete response; SNV/Indel, single‐nucleotide variants and/or insertion/deletions; CNV, copy number variants. In EGFR type, 1 and 2 indicate L858R and exon19 deletions, respectively. , discontinuation by adverse effects; , discontinuation at the request of the patient; , CNV; , SNV/Indel; , both CNV and SNV/Indel existed

Inline graphic — Molecular profile of circulating tumor DNA in plasma samples from patients prior to osimertinib treatment. Fifty‐four patients are shown among whom NGS was successful, from among 57 patients treated with osimertinib, including 3 CR, 27 PR, 19 SD, and 4 PD patients. One patient could not be evaluated for tumor response because of accidental development of cerebral infarction. Single‐nucleotide variants or insertions/deletions deemed to be oncogenic, likely oncogenic, or predicted oncogenic by OncoKB are included. NE, not evaluated; PD, progressive, disease; SD, stable disease; PR, partial response; CR, complete response; SNV/Indel, single‐nucleotide variants and/or insertion/deletions; CNV, copy number variants. In EGFR type, 1 and 2 indicate L858R and exon19 deletions, respectively. , discontinuation by adverse effects; , discontinuation at the request of the patient; , CNV; , SNV/Indel; , both CNV and SNV/Indel existed